Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23789221 | 1.00 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL18908995 | 1.00 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL21568762 | 1.00 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL20467874 | 1.00 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL24335319 | 0.98 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL19681469 | 0.95 | SIRT2 (0.40) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL21018739 | 0.95 | SIRT2 (0.40) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL22138818 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL20841069 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL18911016 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210154188-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210115109-A1 | CONJUGATES AND METHODS OF USE THEREOF FOR SELECTIVE DELIVERY OF IMMUNE-MODULATORY AGENTS | SILVERBACK THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | SILVERBACK THERAPEUTICS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | ARS Pharmaceuticals, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170298139-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | SIRT2 942/4885SIRT1 871/4885SIRT5 1123/4885 |
| US-20170298139-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | SIRT2 4743/4885SIRT1 4682/4885SIRT5 4022/4885 |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | SIRT2 1129/4885SIRT1 1553/4885SIRT5 538/4885 |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | SIRT2 4127/4885SIRT1 4007/4885SIRT5 678/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | SIRT2 973/4885SIRT1 1185/4885SIRT5 1519/4885 |
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | CD74, CD47, CD69 | SIRT2 4165/4885SIRT1 4429/4885SIRT5 4033/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | SIRT2 3167/4885SIRT1 4723/4885SIRT5 4025/4885 |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | SIRT2 4743/4885SIRT1 4682/4885SIRT5 4022/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | SIRT2 4466/4885SIRT1 4147/4885SIRT5 4661/4885 |
| US-20210115109-A1 | CONJUGATES AND METHODS OF USE THEREOF FOR SELECTIVE DELIVERY OF IMMUNE-MODULATORY AGENTS | CD74, CD47, MSR1 | SIRT2 2050/4885SIRT1 2308/4885SIRT5 2745/4885 |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | SIRT2 1129/4885SIRT1 1553/4885SIRT5 538/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | SIRT2 3784/4885SIRT1 4037/4885SIRT5 4142/4885 |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | SIRT2 886/4885SIRT1 859/4885SIRT5 971/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | SIRT2 1353/4885SIRT1 2240/4885SIRT5 2718/4885 |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | SIRT2 886/4885SIRT1 859/4885SIRT5 971/4885 |
| US-20210154188-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ALKBH3 | SIRT2 4638/4885SIRT1 4589/4885SIRT5 994/4885 |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | SIRT2 3167/4885SIRT1 4723/4885SIRT5 4025/4885 |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | SIRT2 973/4885SIRT1 1185/4885SIRT5 1519/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | SIRT2 2353/4885SIRT1 2590/4885SIRT5 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.